Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet J-P, et al. Alzheimers Res Ther. 2011; 3(2):16. Epub 2011 Apr 19. PMID: 21504563. Abstract CommentRecommendBookmarkWatch